Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: Retrospective analysis of 224 cases

European Journal of Haematology

Volumn 81, Issue 5, 2008, Pages 354-363

  Malagola, Michele ^a,j   Peli, Annalisa ^a   Damiani, Daniela ^b   Candoni, Anna ^b   Tiribelli, Mario ^b   Martinelli, Giovanni ^c   Piccaluga, Pier Paolo ^c   Paolini, Stefania ^c   De Rosa, Francesco ^c   Lauria, Francesco ^d   Bocchia, Monica ^d   Gobbi, Marco ^e   Pierri, Ivana ^e   Zaccaria, Alfonso ^f   Zuffa, Eliana ^f   Mazza, Patrizio ^g   Priccolo, Giancarla ^g   Gugliotta, Luigi ^h   Bonini, Alessandro ^h   Visani, Giuseppe ⁱ   Skert, Cristina ^a   Bergonzi, Cesare ^a   Roccaro, Aldo Maria ^a   Filì, Carla ^a   Fanin, Renato ^b   Baccarani, Michele ^c   Russo, Domenico ^a   more..

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f Division of Haematology   (Italy)

^g Division of Haematology   (Italy)

^h Division of Haematology   (Italy)

ⁱ Division of Haematology   (Italy)

^j SPEDALI CIVILI   (Italy)

more..

Author keywords

Acute leukaemia; Fever; Fludarabine; Induction; Infections

Indexed keywords

CYTARABINE; ETOPOSIDE; FLUDARABINE; IDARUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BLOOD TOXICITY; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG FATALITY; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; HYPERBILIRUBINEMIA; INCIDENCE; INFECTION RISK; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYCOSIS; NAUSEA; NONHUMAN; OPPORTUNISTIC INFECTION; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RETROSPECTIVE STUDY; THERAPY DELAY; VIRUS INFECTION; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS; BACTEREMIA; FEMALE; FEVER; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYCOSES; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; VIDARABINE;

EID: 54349092650     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2008.01122.x     Document Type: Article

References (45)

1. Chamilos G, Luna M, Lewis RE, Bodey G, Chemaly R, Tarrand J, Safdar A, Raad A, Kotoyiannis D. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006 91 : 986 9.
2. Cornet M, Fleury L, Maslo C, Bernard JF, Brucker G. Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. Invasive Aspergillosis Surveillance Network of the Assistance Publique-Hopitaux de Paris. J Hosp Infect 2002 51 : 288 96.
3. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998 26 : 781 803.
4. Mattiuzzi GN, Estey E, Raad I, et al. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 2003 97 : 450 6.
5. Muhlemann K, Wenger C, Zenhausern R, Tauber MG. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia 2005 19 : 545 50.
6. Pagano L, Girmenia C, Mele L, et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica 2001 86 : 862 70.
7. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM - 2004 study. Haematologica 2006 91 : 1068 75.
8. Pagano L, Caira M, Picardi M, Candoni A, Melillo L, Fianchi L, Offidani M, Nosari A. Invasive aspergillosis in patients with acute leukemia: update on morbidity and mortality - SEIFEM-C Report. Clin Infect Dis 2007 44 : 1524 5.
9. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 2000 110 : 273 84.
10. Berman E, Arlin ZA, Gaynor J, Miller W, Gee T, Kempin SJ, Mertelsmann R, Andreeff M, Reich L, Nahmias N. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute non lymphocytic leukemia: results of the L-16M protocol. Leukemia 1989 3 : 115 21.
11. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, Gulati S, Andreeff M, Kolitz J, Gabrilove J. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991 77 : 1666 74.
12. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996 87 : 1710 7.
13. Buchner T, Hiddemann W, Wormann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanin: a randomized trial by the German AML Cooperative Group. Blood 1999 93 : 4116 24.
14. Hann IM, Stevens RF, Goldstone AH, Rees JK, Wheatley K, Gray RG, Burnett AK. Randomized comparison of DAT vs ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trials (MRC AML 10). Blood 1997 89 : 2311 8.
15. Kell WJ, Burnett AK, Chopra R, Yin JA, Clark RE, Rohatiner A, Culligan D, Hunter A, Prentice AG, Milligan DW. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 2003 102 : 4277 83.
16. Löwenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly:final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 1998 16 : 872 81.
17. Rees JK, Gray G, Wheatley K. Dose intensification in acute myeloid leukemia: great effectiveness at lower costs. Principal report of MRC AML 9 study. Br J Haematol 1996 94 : 89 98.
18. Tsimberidou A, Estey E, Cortes J, et al. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 2003 97 : 1481 7.
19. Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, Gerber MC, Banks PL. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group. J Clin Oncol 1992 10 : 1103 11.
20. Wiernik PH, Banks PL, Case DC Jr., Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992 79 : 313 9.
21. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1996 88 : 2841 51.
22. Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 1982 60 : 454 62.
23. Malagola M, Damiani D, Martinelli G, et al. Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukemia patients. Br J Haematol 2007 136 : 87 95.
24. Paolini S, Piccaluga PP, Rondoni M, et al. Four-drugs induction intensified regimens (idarubicin, cytarabine and etoposide plus fludarabine or mylotarg - FLAIE and MyAIE) for acute myeloid leukemia. Results of a pilot study. Haematologica 2007 92 : 72.
25. Russo D, Pricolo G, Michieli M, et al. Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia. Leuk Lymphoma 2001 40 : 335 43.
26. Russo D, Malagola M, de Vivo A, et al. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukemia patients. Br J Haematol 2005 131 : 172 9.
27. Russo D, Damiani D, Malagola M, et al. Fludarabine based regimen (FLAI) is an effective treatment for induction of multidrug resistant Pgp-positive acute myeloid leukemia patients. Blood 2005 106 : 1857a.
28. Eichorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006 107 : 885 91.
29. Estey EH, Thall PF, Cortes JE, Giles FJ, O'Brien S, Pierce SA, Wang X, Kantarjian HM, Beran M. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 2001 98 : 3575 83.
30. Keating MJ, Kantarjian H, O'Brien S, Koller C, Talpaz M, Schachner J, Childs CC, Freireich EJ, McCredie KB. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 1991 9 : 44 9.
31. Michieli M, Damiani D, Ermacora A, et al. P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukemic blast cells. Br J Haematol 1997 96 : 356 65.
32. Pallis M, Russell N. Strategies for overcoming p-glycoprotein-mediated drug resistance in acute myeloblastic leukemia. Leukemia 2004 18 : 1927 30.
33. Plunkett W, Gandhi V, Huang P, Robertson LE, Yang LY, Gregoire V, Estey E, Keating MJ. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol 1993 20 : 2 12.
34. Anaissie E, Kotoyiannis D, O'Brien S, Kantarjian H, Robertson L, Lerner S, Keating M. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998 129 : 559 66.
35. Fenchel K, Bergmann L, Wijermans P, Engert A, Pralle H, Mitrou PS, Diehl V, Hoelzer D. Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas. Leuk Lymphoma 1995 18 : 485 92.
36. Morrison VA. The infectious complications of chronic lymphocytic leukemia. Semin Oncol 1998 25 : 98 106.
37. Sanders C, Perez EA, Lawrence HJ. Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine. Am J Hematol 1992 39 : 14 5.
38. Godwin JE, Kopecky JK, Head DR, Willman C, Leith C, Hynes H, Balcerzak S, Appelbaum F. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study (9031). Blood 1998 91 : 3607 15.
39. Heil G, Hoelzer D, Sanz MA, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 1997 90 : 4710 8.
40. Witz F, Sadoun A, Perrin MC, et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Blood 1998 91 : 2722 30.
41. Zittoun R, Suciu S, Mandelli F, et al. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer and Leukemia Cooperative Group. J Clin Oncol 1996 14 : 2150 9.
42. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002 34 : 7 14.
43. de Pauw B, Patterson TF. Should the consensus guidelines' specific criteria for the diagnosis of invasive fungal infection be changed? Clin Infect Dis 2005 41 : S377 80.
44. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001 19 : 253 9.
45. Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, Wilmer A, Verhaegen J, Boogaerts M, Van Eldere J. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005 1 : 1242 50.